SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Genomics... -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (137)3/28/2001 11:39:45 AM
From: nigel bates  Respond to of 360
 
...Lander, who also discussed current public projects, said Celera used the Human Genome Project's sequence data...
"If you use a source of data with 90 percent of the genome, put it in, and get 90 percent at the end, one does occasionally wonder where the beef is," Lander said. "At the moment there is no evidence that the whole genome shotgun method worked at all for the human genome...

The real question might be 'where's the business model?'.

nig



To: tuck who wrote (137)3/28/2001 11:53:14 AM
From: John A. Stoops  Respond to of 360
 
Tuck,

Well maybe this explains the general weakness in the stock performance.

John



To: tuck who wrote (137)3/28/2001 12:24:19 PM
From: Mark Bong  Respond to of 360
 
Haseltine also has been quoted as saying that CRA's software for detecting genes was faulty, and that their gene count is very low. He estimates at least 90,000 genes. Many prominent scientists have supported his view. It looks like Eric Lander is covering his bases to protect his reputation. Will Incyte and HGSI look better if Venter is proved wrong???????


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News